Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule inhibitor of the bifunctional protein GlmU from Haemophilus influenzae. GlmU is an essential enzyme in bacterial aminosugar metabolism, catalyzing the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The inhibitor was identified through high-throughput screening and exhibits micromolar potency against hiGlmU. It binds to an allosteric site adjacent to the substrate-binding region, preventing structural rearrangements required for enzymatic activity. This mechanism provides a basis for structure-guided design of new classes of mechanism-based inhibitors targeting bacterial cell wall biosynthesis[5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide.